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Abstract This study aims to evaluate a single-center experi-
ence with endovascular treatment of cranial dural
arterievenous fistulae (CDAVF). The clinical and radiological
records of 170 consecutive patients harboring a CDAVF and
treated endovascularly in a 16-year period were reviewed. A
variety of data related to demographics, features of the lesion,
treatment, outcome, and follow-up were analyzed with em-
phasis to the results and complications. Half of the lesions had
cortical venous drainage (CVD) in the initial angiographic
investigation, whereas 26 % had exclusively CVD. Sixty-
seven percent of our patients presented with benign symptoms
and 33%with aggressive symptoms. In 60.5 % of the patients
with benign lesion (without CVD), an anatomic cure in the
immediate postinterventional angiogram without complica-
tion or permanent morbidity was achieved, whereas 69 % of
the patients with aggressive lesions (with CVD) had an ana-
tomic cure in the postinterventional final angiogram with all
permanent-morbidity cases belonging to this group. The av-
erage of endovascular operation sessions per patient was 1.2.
In a mean follow-up period of 2.8 years, the overall complete
occlusion rate was 85.5 % (78 % for the benign group and
89.5 % for the aggressive group) and clinical cure and/or
improvement rate of 93 %. The operative mortality was zero,
and permanent neurologic morbidity was 2.3 %. In 73 % of
our cases, N-butyl cyanoacrylate (NBCA) was used as the
only or main embolic material. Endovascular embolization is
the treatment of choice for CDAVF. High rates of good ana-
tomical and clinical results, associatedwith very low operative
complication rate can be achieved with few embolization
sessions. Althoughmastering of a permanent embolic material
is important, the therapeutic strategy should be individulized
and not material based.
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Introduction
Embolization for the treatment of cranial dural arteriovenous
fistulae (CDAVF) was developed as an alternative to open
surgical approach and soon appeared as a more attractive
treatment mainly due to less invasiveness.
Still many aspects regarding etio-pathogenesis, pathophys-
iology, natural history of CDAVF, as well as treatment strate-
gies, effectiveness of endovascular approach, acceptable rate
of complications, and embolic materials need exploration,
better understanding, and answers based on real evidence.
Aiming to contribute mainly in aspects related to the treat-
ment, we studied retrospectively patients treated in our Insti-
tution during the last 16 years.
Patients and methods
This series includes 173 consecutive adult patients who were
evaluated and treated at our institution by the senior author
(AV) in a 16-year period between January 1995 and December
2010. Six patients of this series were treated by the first author
(GB), after joining the department in 2009. Patients treated
before 1995 were excluded because of difficulties to collect
complete data. A retrospective analysis of medical files and
angiographic andMR/CT imaging studies was undertaken. The
last 10 patients were studied prospectively. The angiographic
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images and/or videos of 39 patients could not be accessed;
therefore the data for these patients were collected from the
history chart, interventional report, and CT-MR imaging.
There were 75 women and 98 men. Their age ranged from
22 to 82 years, with a mean age of 56.3 years.
The interval from initial presentation of symptoms to treat-
ment was recorded in 78 patients and varied from 1 week to
10 years, with a mean interval of 10.8 months.
Factors that could be considered as predisposing were
recorded in 19 patients (11 %). History of head surgery related
to the location of the fistula was reported in six patients, severe
upper respiratory infection in three patients, documented sinus
thrombosis in one patient, and incompletely embolized pial
arteriovenous fistula in one patient. In eight cases, a history of
severe head injury was recorded.
We described as aggressive symptoms those related to
either focal or global neurological disturbance (paresis, apha-
sia, ataxia, seizures, etc.) attributed to a hemorrhagic or
nonhemorrhagic central nervous system (CNS) disorder. We
described as benign symptoms those related to local factors
outside or not directly related to the CNS, such as venous
congestion in the orbit with or without cranial nerve deficit,
tinnitus, headache, etc. [13].
Presentation with benign symptoms was recorded in 116
patients (67 %), including 2 patients with incidentally discov-
ered lesions, whereas 57 patients (33 %) presented with ag-
gressive symptoms. Fourteen patients (8%) had extensive and
complex lesions with the majority (12 patients) of these hav-
ing multiple lesions. Five more patients had bilateral lesions.
The clinical presentation appears in Table 1.
All procedures were performed on a biplane angiographic
unit. Percutaneous femoral artery catheterization was used to
achieve access in all patients. Patients were not systematically
heparinized. Standard coaxial techniques were used. The
“Valavanis” 5F catheter (Cook Medical Inc., Bloomington,
IN, USA) was constantly used as both angiographic and
guiding catheter. Microcatheter Elite 1.5F (Stryker Neuro-
vascular, Fremont, CA, USA) was used in all cases over a
soft microwire, preferably Mizzen (Boston Scientific) and
lately Mirage (ev3 Neurovascular, Irvine, CA, USA). Balloon
assistance was employed for distal protection during polyvi-
nyl alcohol (PVA) injection for very small feeders.
Fifteen patients were treated under neuroleptic anaesthesia.
All other embolizations were undertaken under general endo-
tracheal anaesthesia.
Results
Classification
Classification of CDAVF according to location is sometimes a
very difficult task especially in complex and extensive lesions,
which often extend to a certain length along adjacent dural
sinuses and structures withmorphologically undistinguishable
borders. In such lesions, the definition of multiplicity may be
also questionable. In order to preserve accuracy, we list our
cases according to the exact location avoiding round groups,
but still divided in two tables, one with more ordinary loca-
tions (Table 2) and the second with complex topography
(Table 3).
The classifications according to the venous drainage by
Borden et al. [3] and Cognard et al. [7] have been validated
as the best predictors of clinical behavior of a CDAVF and
were used as the main criterion for therapeutic decision mak-
ing. Eighty-seven patients (50 %) presented CVD in the initial
angiographic investigation, whereas 45 (26 %) of the whole
population had exclusively CVD.
The type of venous drainage according to the above
classiffications is summarized in Table 4.
As proposed by Geibprasert et al. [13], the craniospinal
epidural spaces can be categorized into three different com-
partments related to their specific drainage role of the bone
and central nervous system, the ventral epidural (VE), dorsal
epidural (DE), and lateral epidural (LE) groups. In 60 patients,
the CDAVF was allocated in the VE group, in 44 patients in
the DE group, and in 41 patients in the LE group. Twenty-
three patients had a fistula extending into both VE and DE
spaces, five patients in both DE and LE.
Management
Three of the patients of this series were treated conservatively
with manual carotid compression. All three lesions were lo-
cated in the cavernous sinus and had small supply and slow
flow. After this treatment, two patients were asymptomatic
and one improved. The remaining 170 patients were treated
with embolization. Curative embolization was the strategy for
the vast majority of the patients. Palliative or targeted
endovascular treatment was reserved for patients with very
extensive lesions without a chance of complete eradication by
either embolization or surgery.
Combined treatment with surgery was applied in two cases.
In one case of a very extensive shunt and after failure of
palliative treatment to control the patient’s symptoms, a sur-
gical occlusion of the transverse-sigmoid sinuses was
performed, combined with a venous by-pass connecting the
proximal transverse sinus with the jugular vein. In one more
case, surgical intervention was employed after an incomplete
endovascular occlusion. No case was refered for g-knife
treatment.
Embolization procedures
Overall, 209 procedures were performed to treat 170 patients,
with an average of 1.2 sessions per patient and a maximum of
64 Neurosurg Rev (2014) 37:63–71
5 sessions, in a single case. The vast majority, namely, 145
patients, (85 %) was treated with a single endovascular
procedure, whereas 25 patients were treated with staged
procedures (Table 6). Three of our patients had been
treated before (in a total of six embolization sessions) in
other institutions.
In 177 (85 %) sessions, the transarterial approach (TA) was
exclusively used. In 21 sessions (10 %), the transvenous (TV)
approach was used exclusively. This was applied mainly for
cavernous sinus lesions and occasionally for some lesions in
the transverse or/and sigmoid sinus. Combination of TA and
TVapproach was used in 11 sessions.
In 124 patients (73 %), glue was used as the only or
main embolic material. In 49 of these patients, NBCA
alone was used. In 62 patients, NBCA was the main agent
with PVA as supplementary material for residuals, which
persisted following significant obliteration or the shunt
with NBCA. In 13 cases, coils were used in addition. In
19 cases (11 %), mostly cavernous sinus lesions, coils
were used as the only embolic material. In another 27
cases (16 %) pertaining to lesions with either a slow flow
shunt, or to lesions with diffuse supply from very tortuous
distal or just dangerous feeders, solely PVA was used. In
six lesions, balloon assistance was employed.
Immediate angiographic results
Complete occlusion of the CDAVFwas strictly considered the
absence of any arteriovenous shunt in the late angiographic
phases. As subtotal occlusion, was defined an occlusion rate
Table 1 Clinical presentations
Clinical Presentation Patients Percent
Tinnitus alone
Tinnitus+headache and/or dizziness
44
Orbital signs alone (exophthalmus, chemosis, etc.)
Orbital signs+tinnitus with or without headache
Orbital signs+diplopia (nerve paresis)
15
Orbital signs+IVAb+diplopia or tinnitus 7c 4
Hemorrhage (SAH/ICH/IVH/Combination)
Focal neurological disorder
26.5
Epilepsy 7 4
Congestive venous encephalopathy
Dementia
2.3
Headache with or without dizziness 3
Hemifacial spasm and trigeminal neuralgia 1
Discovered incidentally 3 1.7
a One patient presented initially with light exophthalmus and chemosis
and subsequently was admitted with intracerebral bleeding
b IVA for Impaired visual acuity
c From this group, two patients had diplopia and one had tinnitus
Table 2 Ordinary locations
Ordinary Locations Number Percent
Transverse sinusa 28 16
Sigmoid sinus 10 5.8
Transverse sinus and Sigmoid sinus 21 12
Cavernous sinus 27b 15. 6
Tentoriumc 15 8.6
Petrosal vein and Superior petrosal sinus 10 5.8
Convexityd 6 3.5
Jugular bulb 6 3.5
Cribriform plate 5 3
Hypoglossal and condylar canal 5 3
Sphenoid wing-orbital apex 5 3
Foramen magnum 4 2.3
Superior sagittal sinus 3 1.7
Temporobasal− middle cranial fossa 3 1.7
Jugular bulb+sigmoid sinus 3 1.7
Torcular (+/−) transverse sinus 2 1.1
Superior sagittal sinus+transverse sinus 2 1.1
Vein of Galen 2 1.1
Cerebellomedulary cistern 1
Jugular bulb+Inferior petrosal sinus 1
a Transverse sinus without torcular involvement (1 bilateral)
b Three of them bilateral
c Either supra- or infra-tentorial
d Cortical vein without involvement of the sinuses
Table 3 Complex locations
Complex extensive locations Number
Jugular bulb bilateral+F. magnum+clivus+cavernous sinus 1
Jugular bulb+sigmoid sinus+inferior petrosal sinus 1
Jugular bulb+sigmoid sinus+hypoglossal-condylar canal 2
Transverse sinus bilateral+torcula+occipital sinus 1
Transverse sinus+sigmoid sinus+superior sagittal sinus 1
Transverse sinus+sigmoid sinus+jugular bulb 2
Transverse sinus+sigmoid sinus+jugular bulb+hypoglossal-
condylar canal+convexity of posterior cranial fossa
1
Transverse sinus+torcula+sigmoid sinus 1
Transverse sinus+posterior fossa 1
Transverse sinus+contralateral sigmoid sinus 1
Sup. sagittal sinus+tentorium+middle fossa 1
Whole skullbase with predominant jugular bulb 1
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of more than 90 % or a faint opacification of the shunt in the
late arterial phase. Extensive occlusion was considered an
occlusion of approximately 70–90 % of the shunt. An occlu-
sion rate of <70 % was reported as partial occlusion.
In Table 5 appears the relation of operative sessions with
obtained immediate angiographic results.
By summarizing the angiographic results, 112 patients
(66 %) had an immediate complete angiographic occlusion
of their CDAVF, 36 patients (21 %) had a subtotal occlusion,
17 patients (10 %) presented extensive occlusion, and 5 pa-
tients (3 %) had a partial occlusion (2 palliative, one aborted
because of a complication).
Considering the immediate angiographic results in relation
to the venous drainage pattern, a complete occlusion was
achieved in 52 of the 86 patients (60.5 %) with benign lesions
and in 60 of the 87 patients (69 %) with aggressive lesions.
Early clinical outcomes
Early clinical outcome is defined as the clinical condition of
the patient during the period of postoperative hospitalization.
For most of our patients who presented without bleeding, this
period corresponded to 3–5 days.
One hundred sixty patients showed either complete disap-
pearance (tinnitus in most of these cases) or clear improve-
ment of their presenting symptoms (mainly applies to orbital
symptomatology) or did not present a new neurological deficit
postoperatively. This latter refers to patients who (a) were
suffering of some neurological deficit due to presenting
bleeding/ischemia, (b) the presenting symptom was not per-
manent in nature (as epileptic fit), and (c) it was too early to be
evaluated during the immediate postoperative period (as in
cases of dementia or nerve paresis).
Two patients presented temporary worsening of pre-
existing symptoms (decreased visual acuity and chemosis
with exophthalmos and diplopia, respectively). Both patients
showed improvement after steroid administration during their
hospitalization time.
Four patients developed new and permanent symptoms as a
result of an operative complication. Four more patients devel-
oped new but temporary symptoms.
Complications of endovascular treatment
There were four cases of permanent neurological deficit
(2.3 %) due to an operative complication and four cases of
temporary neurological deficit (2.3%) not clearly related to an
operative complication. There was no mortality connected to
an operative complication in this series.
The first case of permanent neurological deficit is related to
an unwanted NBCA migration through a nonidendified col-
lateral, the artery of the foramen lacerum to the middle cere-
bral artery and then to middle cerebral artery (MCA) territory,
which resulted to a severe infarction of the MCA.
In the second case with permanent deficit, spasm of
the superior cerebellar artery (SCA) was detected at the
end of the procedure. However, dissection of the vessel
could not be confidently excluded. The immediate
postembolization employment of an open surgical oper-
ation aiming to a radical excision and the resulting
cerebellar infarct makes the exact estimation of cause
and effect difficult. Nevertheless, we included this case
in the embolization-related complications due to the
possible relation of cerebellar infarct with the alteration
of the SCA detected in the angiogram.
The third case with permanent morbidity was a patient with
X and XII nerve paresis after glue embolization of a jugular-
hypoglossal foramen lesion.
The fourth patient with a torcular CDAVF and cere-
bellar cortical drainage through a varicose vein presented
2 days after embolization cerebellar signs and edema
with later infarction presumably due to venous thrombo-
sis. A decompressive craniectomy was performed, and
the patient showed improvement during the ensuing
weeks.
Three patients presented temporary diplopia immediately
(one patient) and several hours after embolization (two pa-
tients). The two patients improved rapidly after 24 h, whereas
the third patient recovered over several days.
Table 5 Embolization sessions and immediate angiographic results
Sessions Number of
patients
Complete
occlusion
Subtotal
occlusion
Extensive
occlusion
Partial
occlusion
1 145 98 29 13 5
2 15 9 4 2
3 6 3 2 1
4 3 2 1
5 1 1
Total 170 112 36 17 5
Table 4 Venous drainage according to Borden and Cognard classification
Borden Number of patients Cognard Number of patients
Type 1 86 Type I 39
Type IIa 47
Type 2 42 Type IIb 10
Type IIab 32
Type 3 45 Type III 18
Type IV 19
Type V 8
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One more patient with a transverse-sigmoid sinus CDAVF
who presented with a first epileptic attack postoperatively did
not suffer of any detected operative complication.
Follow-up
As a general rule, the first postoperative imaging with CTwas
performed on the same day or the day after the operation. MR
was undertaken during the first 3–5 days after the operation.
Patients were usually evaluated at yearly intervals after
treatment, but in many cases, an individualized approach was
applied. In total, 158 patients were followed-up for 447 patient-
years (mean of 2.8 years ranging from 1 to 15 years). For
patients with known incomplete (subtotal or extensive or par-
tial) immediate angiographic occlusion (InCAO) or cases of
previously complete angiographic occlusion (CAO) with clin-
ical or imaging signs of recurrence, the strategy was defined
according to the specific symptomatology in combination with
the findings of MR. The time of follow-up MR ranged from
3 months to 1 year after the embolization. Patients with aggres-
sive lesions and incomplete immediate angiographic occlusion
would come for MR imaging early (3–6 months) if their
presentation was bleeding, or later (up to 1 year) if their
presentation was other than bleeding. In case of suspicion of
CVD, further DSA and embolization was planned. In case of
failure to eliminate the CVD, surgery was considered.
For 95 patients, the clinical and MR follow-up confirmed
the known CAO of their lesion, whereas 9 patients with
previously CAO had a recurrence. Four patients presented
recurrent clinical symptoms (one with new bleeding) during
follow-up and underwent DSA and further embolization. In
three of these patients a complete occlusion was achieved
whereas for the fourth patient the occlusion was subtotal. Five
patients with a previous CAO, in their regular MR imaging
follow-up presented a recurrent shunt without CVD and with-
out clinical manifestation. They are just followed-up.
Seven recently treated patients with CAO, have no follow-
up examination yet, whereas one more patient with complete
angiographic occlusion died few weeks after his admission as
a consequence of his initial brainstem hemorrhage.
Thirty-five patients with an InCAO in the last embolization
presented a dissapearance of vascular abnormalities (arterial
feeding vessels, shunt, and dilated veins) in the follow-up MR
examination (two had additional surgery) indicating a progres-
sion to complete occlusion of the lesion.
For 13 patients the MR follow-up imaging confirmed the
known InCAO of their shunt; one patient of this group with
persistent CVD presented cerebral bleeding and died. The
remaining 12 patients had no clinical worsening, and 7 of
them had no evidence of CVD; therefore, further follow-up
and neither new embolization nor DSA control were sug-
gested. The remaining five patients with CVD await further
endovascular treatment.
Five recently treated patients with InCAO have no follow-up
yet.
Another five patients were lost to follow-up.
In total, of the 165 embolized and followed-up patients,
141 patients (85.5 %) demonstrated a complete occlusion of
their shunt. Sixty-five of the above patients had benign le-
sions; therefore, the complete occlusion rate for the benign
group was 78 %, whereas 76 patients had aggressive lesions.
Therefore, the complete occlusion rate for the aggressive
group was 89.5 % (Table 6).
In terms of late clinical outcome, 134 patients presented
either clinical cure or no new neurological deficit. Another 14
patients presented improvement of their symptoms during
follow-up period, and 6 more patients had also improvement
after subsidence of postoperative temporary neurological
manifestations. In total, 154 (93 %) of treated and followed-
up patients presented clinical cure or improvement of their
symptoms.
As mentioned, four patients suffered a clinical wors-
ening related to a complication. Another nine patients
(from the group of InCAO) developed recurrent
symptoms.
Three patients died. One died during the initial hospi-
talization due to his presenting intracerebral hemorrhage
(ICH). The second patient died of myocardial infarction,
and the third one died of cerebral bleeding in the follow-
up period.
Table 6 Follow-up according to the postoperative angiographic result
Postoperative
result
Follow-up Number of
patients
CAO Clinical and MR follow-up confirmed the
known CAO (one patient died because
of MI)
95
CAO Clinically recurrent symptoms (1 bleeding).
DSAconfirmed recurrence; re-embolization
(3 complete, 1 subtotal occlusion)
4
CAO MR: recurrent shunt—no CVD—clinically
asymptomatic F-up
5
CAO No follow-up imaging yet (7 patients)
(1 patient died due to initial brainstem
bleeding)
8
InCAO MR: occluded shunt—clinically
asymptomatic F-up
35
InCAO Clinical and MR follow-up confirmed the
known InCAO; 5 patients with CVD
await treatment; rest 7 patients, f-u.
(1 patient with persistent CVD bled
and died)
13
InCAO No follow-up imaging yet 5
InCAO Lost to F-up 5
CAO complete angiographic occlusion, InCAO incomplete angiographic
occlusion
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Discussion
Many reports appeared in the literature during the past years
regarding treatment of CDAVFs [6, 8, 12, 15, 16, 20, 22, 25,
27, 38]. This is one of the largest series of CDAVF including
typical, multiple, and extensive lesions from all intracranial
locations, focusing on endovascular treatment, operative re-
sults, and complications and having a long-term follow-up. It
comprises 170 consecutive patients treated exclusively
endovascularly with the exception of two cases where surgical
intervention was secondarily employed and three cases, which
were treated conservatively.
Aspects of the disease related to the aetiopathogenesis and
pathophysiology do not belong to the scope of this report.
Regarding the clinical presentation, a correlation between
the venous drainage pattern of CDAVFs and the clinical
course has been established [1, 4, 17, 24, 26]. Further aspects
related to presentation and pathophysiology as well as presen-
tation and location in regard to the venous epidural space will
be addressed in future publications.
Generally, conservative treatment and follow-up in benign
lesions with mild or no symptoms is the management of
choice [11]. The patient’s tolerance to otherwise benign symp-
toms and his attitude towards active or conservative treatment
in relation with the anticipated risks played a decisive role in
the management of benign lesions in our series and explain the
high treatment rate.
Complete elimination of the lesion is certainly the ultimate
goal. However, there are extensive and complex lesions,
which involve distal, multiple, and tortuous arterial feeders,
with no possibility of selective approach to the shunting zone
neither transarterially nor transvenously.
In such cases, palliative treatment for control of symptoms
evenwith a nonpermanent embolic agent or targeted treatment
for elimination of the CVD, if detected, may be a reasonable
alternative.
If we examine the patients treated in the present series
divided in two groups, the “benign” group (without CVD)
and the “aggressive” group (those with CVD) including 86
and 87 patients respectively, we will notice that the “benign”
group had no operative complication and permanent morbid-
ity, whereas all permanent-morbidity cases belong to the
“aggressive” group. This is a crucial point to emphasize.
Acceptable treatment for a lesion with low natural risk means
treatment with even lower risk of complications, namely,
complication rate zero or nearly zero.
Progression of some lesions from InCAO to complete oc-
clusion based on MR-imaging criteria is related to the fact that
some cases with an angiographically demonstrated subtotal
occlusion at the end of embolization developed progressive
thrombosis of their shunt and draining vein in the immediate
postoperativeMR or during follow-up. This could be explained
by the observation that a subtotal occlusion of a dural shunt
with faint opacification of the collecting vein in the late arterial
phase, in many cases, represents one step before the complete
thrombosis, which is just a matter of time to occur. This
observation applies also to some cases of partial embolization
with NBCA targeted to the dominant part of the shunt (our data
still anecdotal). However, the limitation of the diagnostic infe-
riority of MR in comparison with the catheter angiogram
should be always kept in mind.
The total percentages of complete occlusion and clinical
cure (85.5 % total—78 % for benign lesions and 89.5 % for
aggressive lesions) and clinical cure (93 %) are among the
highest reported with an associated complication rate among
the lowest [15, 21, 23, 39].
Selectivity is the quintessence of endovascular treatment,
and the core of the lesion is the only target of a selective
endovascular operation.
NBCA is an adhesive, permanent, thrombogenic, and
cheap embolic material with adjustable penetration according
to the mixture, good visibility, and known long-term behavior.
Mastering the use of a material with such properties in
the dural vasculature enables selective, effective, and safe
embolization even through single small feeders. Needless to
emphasize, the material can never be the protagonist of a
neuroendovascular operation. Good anatomical knowledge
and elegant technique are the primary factors for success [14].
Lately, a new liquid nonadhesive polymer (Onyx, ev3
Neurovascular, Irvine, CA, USA) has been introduced and is
meanwhile recommended as the material of choice for the
embolization of CDAVF [8, 30, 35]. The reported series on the
use of Onyx in the treatment of CDAVF are not comparable
with this series in terms of number and composition of cases.
Therefore, at this point in time, no conclusions can be drawn
over the superiority of one over the other material. In any case,
the results presented here, with high anatomic and clinical
cure, low complication rate, and few embolization sessions
per patient using the mentioned embolic materials and espe-
cially NBCA makes comparison with other materials not
meaningful. In addition, it is known that deep penetration of
Onyx to the shunt requires reflux around the microcatheter
and frequently leads to a surprisingly extensive occlusion of
the vascular network around the actual lesion. This is some-
times associated with an unacceptable rate and/or kind of
complications especially for lesions of the cavernous sinus
[18, 25, 34].
Despite its invasiveness, six-vessel angiography remains
the most reliable modality for diagnosing, assessing, and
classifying CDAVF [28].
Magnetic resonance angiography and venography provide
a noninvasive method which despite its limitations related to
suboptimal resolution and definition of flow dynamics [2, 5,
37] offer a reliable and noninvasive alternative for follow-up
of treated patients [31, 33]. In our institution, conventional
MR imaging, MR angiography (3D-TOF-MRA), and TR
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contrast-enhanced MRA are used for the visualization of
CDAVF. Based on our experience and published reports [29,
32], even slightly dilated cortical veins that signify CVD can
be detected with flow sensitive MR techniques.
The indisputable exclusion of a small and slow-flow lesion
[41] or recurrence during follow-up requires a DSA control.
However, in an asymptomatic patient, such a small and/or
slow flow shunt would be rather benign without clinical
significance, and longer follow-up is enough to ensure the
safety of the patient and exclude potential progression to a
higher-grade lesion.
A curative g-knife treatment for benign lesions is, in our
experience, rather unnecessary because it is not completely
clear whether the long-term morbidity rate outweighs the
benign natural course of the disease [36]. Lesions with CVD
have a contraindication for radiosurgery mainly because its
result is not achievable in a timely fashion. Consequently, g-
knife treatment can be used only in the treatment of benign
CDAVF with intolerable symptoms or aggressive CDAVF,
not accessible or not responsive to endovascular treatment or
surgery.
Surgery for the obliteration of CDAVF is frequently associ-
ated with higher risks [19, 40]. However, some groups have
suggested selective surgical disconnection of the draining cor-
tical vein as a minimally invasive and effective treatment for
lesions with CVD [9, 10]. Actually, simple surgical disconnec-
tion of the cortical venous reflux may be a good option in the
management of patients with aggressive and easily aproachable
lesions, when anatomic features prevented endovascular access
or embolization failled.
Combined endovascular and surgical treatment was practi-
cally a rare exception in our series.
Conclusion
Endovascular embolization is the treatment of choice for
CDAVFs. High percentage of anatomical cure or subtotal-
extensive occlusion of the lesion with even higher rates of
excellent clinical results, associated with very low operative
complication rate can be achieved with few embolization
sessions per patient. According to our experience, these results
can be reliably achieved with a concept of selective attack of
the arteriovenous shunt and specifically its venous component,
bymastering atraumatic superselectivemicrocatheterization as
well as the use of certain permanent embolic materials. Tailor-
ing the therapeutic strategy according to the individual case is
mandatory. Overtreatments and aggressive material-based ap-
proaches, ignoring the actual angioarchitecture, the clinical
aspect and course of the disease should be avoided.
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Comments
Timo Krings, Toronto, Canada
This is one of the largest single-center series on the treatment of dural
arteriovenous fistulae that highlights the high success rates and the low
complication rates if anatomy is respected and the nature of the disease is
understood. One of the major benefits of this article is the long follow-up that
allows the reader to deduce that once stable obliteration of the DAVF is
obtained, chances of recurrence are very low. The manuscript also demon-
strates the goal of treatment in cranial dural arteriovenous fistulae, i.e., the
obliteration of the transition between the arterial and venous segment. It is not
the type of embolizing agent that will make a difference in complication and
cure rate but instead the knowledge of the supply to the cranial nerves and
prediction of the existence and location of the so-called “dangerous” EC-IC
anastomoses especially at the level of the cavernous sinus that has to be
mastered to obtain the results presented in this article. Or, as Pierre Lasjaunias
used to phrase it: “Anatomy is the cheapest way to safe.”
Giuseppe Lanzino, Rochester, USA
With better understanding of their angioarchitecture and patho-
physiology, continuous refinement of endovascular materials and
techniques, most intracranial dural arteriovenous fistulas (DAVFs)
can nowadays be effectively treated with very low morbidity and
mortality. In their monumental series encompassing 16 years,
Baltsavias and Valavanis report their experience with embolization
of 170 consecutive patients with intracranial DAVFs. Sixty-seven
percent of patients suffered from benign symptoms (usually related
to high-flow conditions) such as bruit and conjunctival injection,
while the remaining presented with an aggressive clinical picture.
Immediate anatomic cure was achieved in 60.5 % of patients with
benign symptoms and 69 % of those with aggressive lesions. These
rates of complete anatomical obliteration increased to 78 % for the
benign group and 89.5 % for the aggressive DAVFs. There was no
mortality in this series, and the permanent morbidity rate was very
low (in the low single digits). This remarkable experience illustrates
what can be achieved today with endovascular techniques in the
hands of a recognized master with incredible skills and experience.
The availability of different treatment modalities (which are
often complementary) allows the treating physician to individualize
treatment based on the clinical and radiological characteristics of
the specific patients. Patients with minimally symptomatic fistulas
without retrograde cortical venous drainage can be safely managed
conservatively, and in several cases, I have observed remarkable
spontaneous regression of the fistula, including spontaneous occlu-
sion. Because of this, I believe that some of those cases that have
been described to resolve after intermittent carotid compressions
might indeed represent just the benign natural history and
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evolution of some of these lesions independent of the intermittent
compression. Patients with disabling symptoms associated with
high-flow conditions, in the absence of retrograde cortical venous
drainage, are offered at our Institution, transarterial particulate
embolization with the idea of “palliate” their symptoms. This
approach (using particles greater than 150 μm in the external
carotid artery branches) is extremely safe and effective in resolving
patients’ symptoms. Often, this strategy of transarterial PVA em-
bolization is combined with gamma knife radiosurgery. Gamma
knife is extremely effective in achieving complete obliteration
within usually 1 year, especially in the case of transverse/sigmoid
sinus and cavernous sinus DAVFs. In patients with aggressive
clinical symptoms, we try to achieve a rapid cure. In these cases,
coil embolization of the involved venous drainage usually through
a transvenous approach remains our treatment of choice particular-
ly for indirect cavernous sinus fistulas. Patients with exclusive
retrograde cortical venous drainage are in our hands often effec-
tively treated with transarterial Onyx embolization, especially when
a straight feeder such as the posterior branch of the middle men-
ingeal artery is available for embolization. With the availability of
these complementary non invasive solutions, it is uncommon
nowadays to recur to surgical interruption of the fistula. However,
surgery is still a valid option when endovascular techniques are not
effective, and patients have presented with aggressive symptoms or
have significant retrograde cortical venous drainage.
Karel terBrugge, Toronto, Canada
I have read with great interest the manuscript by Baltsavias and
Valavanis regarding their large experience with endovascular management
of patients with intracranial dural arteriovenous fistulas (SDAVFs). The
team of Professor Valavanis is well known and well accomplished, and
their management outcome resulted in an 89.5 % obliteration rate of
DAVFs with cortical venous reflux using predominantly glue as the
embolic agent of choice. The associated permanent complication rate
was 2.3 %. In the so-called benign DAVFs, a cure was confirmed on
follow up in 78 % of treated patients and no permanent complications
occurred. Publication of this experience is very timely in view of the
shift towards the use of ONYX as the embolic material of choice for
the endovascular management of this condition, and the current publi-
cation will serve as a standard against which other treatment modalities
outcomes can be compared. We congratulate the Zurich team on this
excellent work. KTB
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